Quark Pharma IPO collapses
Quark Pharmaceuticals, the Fremont, Calif., biotech chameleon that tried to portray itself as a hot new RNAi company, has withdrawn its IPO. See our story at VentureBeat Life Sciences.
Next Story: Implantable lens maker Eyeonics aims for $86M IPO
Previous Story: Quark Pharma withdraws its long-shot IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.